Kestra Medical Technologies, Ltd. (KMTS) Fair Value 2026

KMTS · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.8 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (17/100)

Quick Summary — As of 2026-08-28, Kestra Medical Technologies, Ltd. (KMTS) trades at $25.64. QOC: 5.8/10. Value Trap Risk: 17/100 (SAFE). 0/13 models active.

Key Facts

Ticker
KMTS
Price
$25.64
Quality Score
5.8/10
Value Trap Risk
17/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give KMTS?

0 Intrinsic Value Models vs. Current Price ($25.64)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Kestra Medical Technologies, Ltd. (KMTS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Kestra Medical Technologies, Ltd. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About KMTS?

0 of 13 models are currently active for KMTS. See which stocks rank higher →

How Does KMTS Rank in Medical Instruments & Supplies?

Among 56 Medical Instruments & Supplies stocks, KMTS ranks #40 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.

See all Most Undervalued Medical Instruments & Supplies Stocks →

Kestra Medical Technologies, Ltd. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is KMTS a Value Trap?

CirclFi's Value Trap algorithm assigns KMTS a score of 17/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Kestra Medical Technologies, Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Kestra Medical Technologies, Ltd. is rated at 5.8/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every KMTS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Kestra Medical Technologies, Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

11 related Medical Instruments & Supplies stocks with 13-model coverage

STXSStereotaxis, Inc.QOC 6.1BNGOBionano Genomics, Inc.QOC 5.8XRAYDENTSPLY SIRONA Inc.QOC 6.1HBIOHarvard Bioscience, Inc.QOC 5.8POCIPrecision Optics Corporation, Inc.QOC 6.1CUPRCuprina Holdings (Cayman) LimitedQOC 5.6ZJYLJin Medical International Ltd.QOC 2.9UTMDUtah Medical Products, Inc.QOC 8.2STAASTAAR Surgical CompanyQOC 6.8ISRGIntuitive Surgical, Inc.QOC 9.4RMDResMed Inc.QOC 9.4

Read investment analysis: STXS · BNGO · XRAY · HBIO · POCI · CUPR · ZJYL · UTMD · STAA · ISRG · RMD

Which Other Stocks Have a Similar Quality Score to KMTS?

7 companies across all industries closest to KMTS’s Quality of Company score of 5.8/10.

ADVAdvantage Solutions Inc.QOC 5.8SLESuper League Enterprise, Inc.QOC 5.8NGLNGL Energy Partners LPQOC 5.8ATCHAtlasClear Holdings, Inc.QOC 5.8GLXYGalaxy DigitalQOC 5.8JOBYJoby Aviation, Inc.QOC 5.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ADV · SLE · NGL · ATCH · GLXY · JOBY · NVDA

Where Does KMTS Sit in CirclFi's Medical Instruments & Supplies Rankings?

KMTS is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About Kestra Medical Technologies, Ltd.’s Valuation?

What is Kestra Medical Technologies, Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Kestra Medical Technologies, Ltd. (KMTS). The Quality of Company score is 5.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is KMTS overvalued or undervalued right now?

At $25.64, 0 of 0 active models suggest KMTS may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Kestra Medical Technologies, Ltd.'s business model in Medical Instruments & Supplies.

What does a Quality of Company score of 5.8 mean for KMTS?

Kestra Medical Technologies, Ltd.'s QOC of 5.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on KMTS?

CirclFi analyzes KMTS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is KMTS a value trap in 2026?

Kestra Medical Technologies, Ltd.'s Value Trap score is 17/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Kestra Medical Technologies, Ltd. (KMTS) a Quality of Company score of 5.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/KMTS/ · Methodology
Primary sources for this KMTS valuation
  • Financial statements: Kestra Medical Technologies, Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001877184) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for KMTS as of ; valuations recomputed .